Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
J.F.R. Robertson(University of Nottingham), Matthew J. Ellis(Washington University in St. Louis)
Cited by 599
Related Papers
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
|Journal of Clinical Oncology|2001|1.1k
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2010|823
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
|Breast Cancer Research|2011|184
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
|Cancer Discovery|2022|133